Get In Touch

Epithelial ovarian cancer is a disease in which malignant cells develop in the tissue that covers the ovary. Epithelial ovarian cancer is common in women who have a close relation such as mother, daughter, or sister diagnosed with the disease. In case of women having two or more blood relatives with ovarian cancer, the risk of developing the disease is higher. The hereditary information is carried from one generation to another through carrier genes received from parents. It has been estimated that hereditary ovarian cancer is approximately 5% - 10% more prevalent when compared to other cases of ovarian cancer.

Symptoms of epithelial ovarian cancer include pain in the pelvis area, swelling in the abdomen, and gastrointestinal problems such as bloating, etc. Diagnosis of epithelial ovarian cancer is conducted through a series of procedures such as pelvic examination, ultrasound, CA 125 assay, barium enema, intravenous pyelogram (IVP), CT scan, and biopsy.

Epithelial ovarian cancer starts from the surface layer of the ovary. It has been estimated by the Cancer Research UK that 90% of the diagnosed ovary cancers are of this type. The epithelial ovarian cancer market can be classified on the basis of types of epithelial ovarian cancer, diagnostic techniques, and treatment methods. On the basis of type, the epithelial ovarian cancer market can be segmented into five categories: stage I, stage II, stage III, and stage IV. According to the Cancer Research UK, serous epithelial ovarian cancer accounts for two-third of the epithelial ovarian cancer diagnosed every year, while 10% of the epithelial ovarian cancer diagnosed are of undifferentiated type. Different types of treatments are available for patients suffering from epithelial ovarian cancer such as surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy.

In surgery, the uterus, cervix, fallopian tubes, ovaries, and omentum are removed from the body which may include. Post-surgery, patients are treated with radiation therapy and chemotherapy in order to kill the remaining tumor cells. Primary drugs used for the chemotherapy of epithelial ovarian cancer patients include BEP, carboplatin-taxon, gemcitabine-cisplatin, and VeIP. In addition to these, two other therapies for the treatment of epithelial ovarian cancer are under clinical trials such as biologic therapy and targeted therapy. Biologic therapy uses the patient’s immune system to fight against cancer, while targeted therapy involves the usage of drugs that identify and kill cancer-affected cells without causing any harm to the normal cells. Bevacizumab and PARP inhibitors are two such drugs under clinical trials for targeted therapy. Other major drugs under clinical trials include trebananib, paclitaxel, CVac, cositecan, and trabectadin.

According to the National Cancer Institute, in U.S., 22,240 new cases were diagnosed with ovarian cancer and the disease was responsible for 14,030 deaths. Such high rate of incidence and mortality is driving the epithelial ovarian cancer market. Asia Pacific represents the highest opportunity for epithelial ovarian cancer market owing to the increase in number of epithelial ovarian cancer and rise in awareness about the disease. Statistics released by the Cancer Australia revealed that in 2010, there were 1,305 new cases of ovarian cancer in Australia and around 1,470 and 1,640 new cases of ovarian cancer were predicted to be diagnosed in 2014 and 2020, respectively.

Increase in incidences of ovarian cancer, rise in research and development in drugs, favorable reimbursement provisions in developed and developing economies, development in healthcare infrastructure, and surge in government initiatives to promote research and awareness about the disease are projected to drive the epithelial ovarian cancer market during the forecast period. However, the high cost of treatment, stringent regulation in drug testing, and lack of skilled professionals for early diagnosis of disease are anticipated to hinder the growth of the market.

The global epithelial ovarian cancer market can be divided into five geographical region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the epithelial ovarian cancer market, followed by Europe, due to high prevalence of the disease and extensive research and development activities. Increase in incidences of ovarian cancer is expected to drive the global epithelial ovarian cancer market in Asia Pacific during the forecast period. Latin America and Middle East & Africa region are also anticipated to provide lucrative opportunities to the epithelial ovarian cancer market in the next few years. It can be largely ascribed to the growing biopharmaceutical industry in the region and the rise in participation of private players for expanding their geographical presence.

Major players in the epithelial ovarian cancer market include Boehringer Ingelheim GmbH, Millennium Pharmaceuticals, Inc., Amgen, Inc., ImmunoGen, Inc., Pharmacyclics, Inc., Bayer AG, Synta Pharmaceuticals Corp., Prima BioMed, Ltd., Oasmia Pharmaceutical AB, and Glycotope GmbH.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Epithelial Ovarian Cancer Market

Pre Book